Well known in his field as an authority on the design, development and testing of vaccines for adults and children, over the past eighteen months, his capacity as Director of the Oxford Vaccine Group has catapulted him to wider recognition as a public figure in the fight against COVID-19. The development of the Oxford-AstraZeneca vaccine has had an immeasurable impact on the lives of children and young people across the world. His wider work has also had a profound impact on childhood immunisation in the UK, supporting the introduction of half of the vaccines currently given to children.
Andrew obtained his medical degree at St Bartholomew’s Hospital Medical School, University of London in 1989 and trained in Paediatrics at Birmingham Children’s Hospital, UK, specialising in Paediatric Infectious Diseases at St Mary’s Hospital, London, UK and at British Columbia Children’s Hospital, Vancouver, Canada. He obtained his PhD at St Mary’s Hospital, London, UK in 1999 studying immunity to Neisseria meningitidis in children and proceeded to work on anti-bacterial innate immune responses in children in Canada before returning to his current position at the University of Oxford, UK in 2001.